5 Key Takeaways
-
1
Diabetic retinopathy and age-related macular degeneration are leading causes of irreversible blindness in working-aged and older patients, respectively.
-
2
Anti-VEGF therapy is the primary treatment for diabetic macular edema and neovascular AMD, often requiring long-term administration.
-
3
Refractive errors are frequently overlooked in patients receiving anti-VEGF therapy, yet correcting these errors is vital for maximizing visual acuity.
-
4
Recent studies indicate that small refractive shifts occur during anti-VEGF treatment, suggesting that updating refractions may be beneficial even with persistent edema.
-
5
Salabati et al's research recommends offering updated refractions to patients with DME undergoing anti-VEGF therapy, challenging current clinical practices.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.